Manchester Capital Management’s AstraZeneca AZN Stock Holding History

Manchester Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$279K	Buy	1,415 +57	+4%	+$11K	0.04%	231
2025 Q4	$250K	Buy	1,358 +1,312	+2,852%	+$230K	0.03%	246
2025 Q3	$7.06K	Buy	+46	New	+$6.96K	﹤0.01%	912
2021 Q3	–	Sell	-71	Closed	-$8K	–	1032
2021 Q2	$8K	Buy	+71	New	+$7.79K	﹤0.01%	512
2015 Q1	–	Sell	-1,731	Closed	-$122K	–	568
2014 Q4	$122K	Sell	1,731 -903	-34%	-$64.7K	0.02%	493
2014 Q3	$188K	Buy	2,634 +935	+55%	+$68.4K	0.03%	359
2014 Q2	$126K	Buy	+1,699	New	+$123K	0.02%	506

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Manchester Capital Management's AZN Position: Q1 2026 in Review

Manchester Capital Management increased its AstraZeneca (AZN) stake by 4.2% in Q1 2026, buying an estimated $11K and bringing the position to 1,415 shares worth $279K. The position accounts for 0.04% of the portfolio, ranked #231.

Manchester Capital Management first reported a position in AZN in Q2 2014 and has held it in 7 quarters since. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Manchester Capital Management held 1,415 shares of AstraZeneca worth $279K as of Q1 2026.
Manchester Capital Management bought 57 AstraZeneca shares in Q1 2026, an estimated $11K.
AstraZeneca made up 0.04% of Manchester Capital Management's portfolio in Q1 2026, its #231 holding.
Manchester Capital Management first reported a position in AstraZeneca in Q2 2014 and has held it in 7 quarters since.
1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.